Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
NHS and Kite sign access deal for Kite’s cancer cell therapy TecartusNHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell Share XNHS and Kite sign access deal for Kite’s cancer cell therapy Tecartushttps://pharmaphorum.com/news/nhs-kite-cancer-therapy/
NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
NICE backs drugs for lymphoma and lung cancer from Roche and PfizerNICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for Share XNICE backs drugs for lymphoma and lung cancer from Roche and Pfizerhttps://pharmaphorum.com/news/nice-backs-drugs-for-lymphoma-and-lung-cancer/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
NICE rejects Roche’s Polivy combination in advanced lymphomaEngland’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with Share XNICE rejects Roche’s Polivy combination in advanced lymphomahttps://pharmaphorum.com/news/nice-rejects-roches-polivy/
Nearly half of lymphoma patients alive after Gilead’s CAR-T therapyNearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, Share XNearly half of lymphoma patients alive after Gilead’s CAR-T therapyhttps://pharmaphorum.com/news/nearly-half-of-lymphoma-patients-alive-after-gileads-car-t-therapy/
Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
Bayer’s Aliqopa gets speedy review for marginal zone lymphomaThe FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share XBayer’s Aliqopa gets speedy review for marginal zone lymphomahttps://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/
